This study aimed to characterize the incidence, etiology and outcome of infectious episodes in patients with steroid refractory acute GvHD (SR-GvHD). The cohort included 127 adults treated with inolimomab (77%) or etanercept (23%) owing to acute 2-4 SR-GvHD, with a response rate of 43% on day +30 and a 4-year survival of 15%. The 1-year cumulative incidences of bacterial, CMV and invasive fungal infection were 74%, 65% and 14%, respectively. A high rate (37%) of enterococcal infections was observed. Twenty patients (15.7%) developed BK virus-hemorrhagic cystitis and five percent had an EBV reactivation with only one case of PTLD. One-third of long-term survivors developed pneumonia by a community respiratory virus and/or encapsulated bacteria, mostly associated with chronic GvHD. Infections were an important cause of non-relapse mortality, with a 4-year incidence of 46%. In multivariate analysis, use of rituximab in the 6 months before SCT (hazard ratio; HR 4.2; 95% confidence interval; CI 1.1-16.3), severe infection before SR-GvHD onset (HR 5.8;3) and a baseline C-reactive protein 415 UI/mL (HR 2.9; 95% CI 1.1-8.5) were associated with infection-related mortality. High rates of opportunistic infections with remarkable mortality warrant further efforts to optimize long-term outcomes after SR-GvHD.
INTRODUCTION
Acute GvHD (aGvHD) is the most important cause of non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (alloSCT). 1 Refractoriness to steroids, which occurs iñ 50% of patients, is associated with a dismal prognosis. Although multiple second-line therapies have been tested, none of them has remarkably improved long-term outcomes. 2 In 2013 our group published a large series of patients who received inolimomab, a monoclonal Ab targeting the interleukin-2 receptor, as salvage therapy for steroid refractory (SR)-GvHD. 3 Only one-third of responding patients became long-term survivors and opportunistic infections were a major concern, being the main cause of death in 27% of the cases. Severe infections have also been described after the use of other salvage agents for SR-GvHD, 4 although there is a paucity of studies specifically focusing on etiology and outcome of these complications.
In the current study we analyze the occurrence, risk factors and impact on long-term outcomes of severe infections in patients with SR-GvHD treated with inolimomab (before 2014) or etanercept, a TNF-alpha inhibitor (since 2014).
PATIENTS AND METHODS

Inclusion criteria and transplant characteristics
Between January 1999 and June 2015, 127 adult patients developed grade 2-4 SR-acute GvHD after alloSCT at the Hospitals Sant Pau and Vall d'Hebrón in Barcelona and received salvage treatment with inolimomab or etanercept. Both institutions shared homogenous transplantation platforms, including GvHD management and anti-infectious measures. The follow-up of cases from a previous study 3 was updated and additional data were included.
Patients with classical and late-onset aGvHD, as well as those with overlap syndrome but with predominantly features of acute GvHD were included.
Supportive care and anti-infectious prophylaxis. Supportive measures included in all instances antiviral and antifungal prophylaxis, and cotrimoxazole or pentamidine prophylaxis. Antiviral prophylaxis consisted of low-dose acyclovir (400 mg twice a day intravaneously or its equivalent oral doses). Broad spectrum (other than fluconazole) antifungal prophylaxis was used in 92 (73%) patients (see Table 1 ). However, the timing and duration of prophylaxis varied considerably between patients. Serial blood monitoring using quantitative PCR for CMV and EBV infection was done 1-2 times a week. 5 EBV monitoring was introduced in 2006. Pre-emptive anti-CMV therapy was started after PCR41000 DNA viral genome/mL in one serum sample or two consecutive samples with 4500 copies/mL. Patients with EBV viral loads 41000 copies/mL on at least two consecutive occasions or those with one determination 42000 copies/mL were treated with rituximab. Serum galactomannan (2-3 times per week) was included in the monitoring strategy in patients receiving fluconazole prophylaxis.
Anti-cytokine treatment schedule. Inolimomab was administered intravenously at a dose of 11 mg/day for 3 days, 5.5 mg/day for 7 days, and 5.5 mg every other day for five doses (21 days per course). Sixty-six patients (52%) received one course of inolimomab and 32 (22%) received two courses owing to absence of response or relapse after responding to a first course. Etanercept was administered subcutaneously at a dose of 25 mg two times per week for four doses and 25 mg once per week for other four doses. Twenty-eight patients (22%) received one course of etanercept and one received two courses. In addition to steroids, other prior immunosuppressors were not discontinued at the start of the anti-cytokine treatment. 
Definitions
Risk assessment. Advanced disease status was defined as acute leukemia in ⩾ 2nd CR, myeloproliferative disease in accelerated/blast phase or ⩾ 2nd CR, Hodgkin's disease and follicular lymphoma in ⩾ 3rd CR, and large B-cell lymphoma or multiple myeloma in ⩾ 2nd CR. Patients with PR or persistent disease at SCT (except for multiple myeloma) were also considered as advanced disease status. Abbreviations: BM = bone marrow; CB = cord blood; CMPs = chronic myeloproliferative syndrome; GI = gastrointestinal tract; HD = Hodgkin disease; MDS = myelodysplastic syndrome; MM = multiple myeloma; NA = not available; NHL = non-Hodgkin lymphoma; NR = no response; ORR = overall response rate; PB = peripheral blood; SCT = stem cell transplantation; SR-GvHD = steroid refractory acute GvHD. a Broad spectrum AFP was: low dose (1 mg/kg/day) amphotericin B for 60 patients, posaconazol (n = 10), itraconazol (n = 8), caspofungin (n = 8), voriconazol (n = 3), 3 mg/kg amphotericin B (n = 2) and micafungin in one case. The recurrent cases of infection included 18 bacterial infections (six coagulase-negative staphylococci, six enterococcus, three P. aeruginosa, two E. Coli and one Clostridium difficile) and 14 cases of CMV reactivation.
Infections after steroid-refractory acute GvHD I García-Cadenas et al GvHD-related. Diagnosis of aGvHD was based on clinical findings and confirmed with histological evaluation if possible. The overall grading system established by Przepiorka et al. 6 was used. Grades II-IV were treated with prednisone, usually 2 mg/kg/day. Failure of corticosteroids was defined as overall aGvHD grade progression within 4 days of treatment, absence of any response by day 7 or less than partial response by day 14. No patients were excluded because of active infection, poor performance status, or any other cause. All patients gave their informed consent, and the monoclonal Ab was administered as compassionate use after approval by the institutional and national health authorities.
GvHD response was assessed weekly after the initiation of rescue therapy. CR was defined as the sustained disappearance of all GvHD-related clinical and laboratory features, whereas PR was an overall improvement of at least one grade without progression in any organ. The overall response rate included CR plus PR rates. Improvement in one organ but progression in another was considered progression. No response included stable or progressive aGvHD and/or the need for additional salvage therapy.
Infection-related definitions. Infection-related mortality (IRM) was defined as death attributable to a recent severe infection by the primary physician (s) and the coordinator of the study (IG). Any bacterial, viral or invasive fungal infection (IFI) requiring i.v. treatment or prolonging hospitalization were also included. All cases of CMV and EBV infection were reported. Infection data were collected retrospectively until the patient's death or last follow-up according to the Infectious Diseases Working Party of the EBMT guidelines (http://www.ebmt.org/Contents/About-EBMT/Who WeAre/ScientificCouncil/Documents/IDWPdefinitions.pdf). Other severe viral infections included were: (i) disseminated varicella-zoster virus (VZV) infection; (ii) Human Herpesvirus 6 encephalitis, diagnosed by positive PCR from cerebrospinal fluid; (iii) Adenovirus disease, diagnosed when adenovirus was identified in samples from an affected organ(s) by immunohistochemistry; (iv) pneumonia owing to a community respiratory virus; and (v) BK polyomavirus-related hemorrhagic cystitis. [7] [8] [9] Statistical analysis
The primary end point of the study was analyzing the cumulative incidence (Cum.Inc.) of IRM and establishing its major risk factors, whereas secondary end points were description of the major types of severe infections and the possible impact of the type of salvage anti-cytokine used on the risk of IRM. Crosstabs and Student's t-test were used to identify baseline characteristics associated with this end point. Factors with P-value o0.1 in univariate analysis were entered into a multivariate proportional hazards Cox regression analysis. 10 P-values o 0.05 were considered statistically significant, and the hazard ratios (HRs) and their 95% confidence intervals (95% confidence interval; CIs) were calculated. All outcomes except OS were analyzed as Cum.Inc. with the corresponding competing risk factors. Data were analyzed using SPSS.V.15 (SPSS Inc, Chicago, IL, USA) and the CMPRSK package in R 2.4.1. Unless specified otherwise, all time periods described and analyzed refer to the onset of SR-GvHD and not to day 0 of the SCT. Table 1 summarizes the study population. The median age was 51 years (range: 17-70) and 94.5% had an intermediate or high (⩾4) EBMT risk score before SCT. Ninety-five patients (75%) were CMV seropositive and 89 (70%) had presented a severe infection before SR-GvHD development. Broad spectrum antifungal prophylaxis that is, active against invasive mold infections, was used at some point in 92 cases (73%). The median follow-up for survivors was 583 (37-5329) days.
RESULTS
Patient characteristics
GvHD outcomes
Acute GvHD occurred at a median of 34 days after alloSCT (range 7-250). Eight patients (6.3%) had grade II, 71 (56%) grade III and 48 (37.8%) grade IV aGvHD when refractoriness to steroids was established. Involved organs were the gastrointestinal tract in 119 cases (93.7%), the liver in 95 (74.8%) and the skin in 88 (69.3%) cases. Salvage anti-cytokine therapy was started at a median of 14 (range: 4-122) days after GvHD onset. Inolimomab was the rescue option in 98 patients (77.2%), whereas 29 (22.8%) received etanercept. Forty-five of the 98 patients (46%) in the inolimomab group and 12 of the 29 (41.3%) in the etanercept group received the monoclonal Ab as first-salvage treatment. The remaining patients received this treatment after failure of prior salvage therapy. The overall response rate on day +28 was 42.5% (CR 14%) without differences between both monoclonal Ab (see Table 1 for details).
Nature and incidence of severe infections The incidence of the major severe infections by type and time period are summarized in Table 2 .
Bacterial and fungal infections. Seventy-seven patients (61%) had severe bacterial infections at a median of 36 days (range: 0-3321) after the diagnosis of SR-GvHD, with 34% having 41 episode.
The 1-year Cum.Inc. of bacteremia was 73.5% (95% CI 63.5-83.5). Forty-five cases (35.4%) were due to coagulase-negative Staphylococci, while enterococcal bacteremia was documented in 35 (27%) cases. Infections by Gram-negative bacteria occurred Abbreviations: BM = bone marrow; CB = cord blood; Cum.Inc. = cumulative incidence; CI = confidence interval; HD = Hodgkin disease; HHV = human herpesvirus; LRTI = lower respiratory tract infection; NHL = non-Hodgkin lymphoma; PB = peripheral blood; PTLD = post-transplant lymphoproliferative disease.
a Respiratory viruses isolated from lower respiratory tract samples included six influenzae, six respiratory syncytial virus, three parainfluenzae, one rinovirus and one metaneupmovirus. b Mould infections were caused by Aspergillus spp in 14 cases. One case was due to a mucor and there was one IFI due to Fusarium spp.
Infections after steroid-refractory acute GvHD I García-Cadenas et al in 24 cases (19%), and six patients (4.7%) presented C. difficilerelated colitis. We identified seven patients (5.7%) who developed multidrug-resistant infection. The most frequent organisms were as follows: Stenotrophomonas maltophilia (3), vancomycin-resistant enterococci (2), Acinetobacter Baumannii (1), Pseudomonas aeruginosa (1). In 25 cases (32%) bacterial infections were fatal.
Sixteen patients (12.6%) developed an IFI, including probable and proven forms. Invasive aspergillosis was the most common IFI, accounting for 87% of cases, in addition to one case of mucormycosis and one fusariosis. Five patients were under low dose Amphotericin B lipid complex prophylaxis (1 mg/kg/days) at the time of IFI diagnosis. The 1-year Cum.Inc. of invasive aspergillosis was 14.2% (95% CI 4. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Most of the cases (75%) occurred in the first 100 days of SR-GvHD, with a median onset of 28 days (range 3-2575).
CMV and other viral infectionsi. The rate of CMV reactivation was 51.2%, with a 100-day and 1-year Cum.Inc. of 57.3% (95% CI 47-68%) and 67.5% (95% CI 56.6-79%), respectively. Forty-four patients (34.6%) had one or more recurrent episodes. CMV disease occurred in 18 patients, in six of them without a prior diagnosis of CMV infection. The organ involved was predominantly the gastrointestinal tract (n = 11), followed by the lung (n = 7). Only one patient died owing to CMV disease.
Twenty patients (16%) had grades II to IV BK polyomavirusrelated hemorrhagic cystitis at a median of 31 days after the diagnosis of SR-GvHD (range: 0-94). EBV infection was documented in 4 of the 79 monitored patients (5.1%). The only case of EBV-related PTLD occurred before the introduction in our standard practice of routine PCR screening for EBV DNAemia.
Pneumonia by a community respiratory virus was found in 13.4% of patients, with several cases (8/17) documented in long-term survivors (41 year after the onset of SR-GvHD) who suffered moderate-to-severe cGvHD. Other severe viral infections are shown in Table 2 .
IRM and OS Table 3 shows in detail the number, incidence and causes of IRM, NRM and deaths owing to relapse. Initially, we analyzed the Abbreviations: Cum.Inc. = cumulative incidence; IRM = infection-related mortality; NRM = non-relapse mortality; OS = overall survival; SR-GvHD = steroid refractory acute GvHD; 95% CI = 95% confidence interval. 1 PTLD, 1 disseminated VZV, 1 disseminated adenovirus; SR-GvHD steroid refractory graft versus host disease); aGvHD: acute GvHD; cGvHD: chronic GvHD. 1 Severe hemorrhage, 1 distress respiratory syndrome. Overall survival
Days from SR-GVHD diagnosis to last follow-up 4-year overall survival: 15% (7.7-22%) Figure 2 . 4-year overall survival probability estimate, calculated for all 127 patients from the start of salvage therapy for steroidrefractory acute GvHD. A full color version of this figure is available at the Bone Marrow Transplantation journal online.
Infections after steroid-refractory acute GvHD I García-Cadenas et al impact of year of alloSCT (and of SR-GvHD) on long-term outcomes and found that NRM, IRM and OS were equivalent over time (data not shown). IRM and OS at 4 years were 46% (95% CI 31-61%) and 15% (95% CI 7.7-22%), respectively, as shown in Figures 1 and 2 . Acute (56.1%) or chronic (9.5%) GvHD was considered the most common primary cause of death, followed by infections (27.6%). Median time to IRM was 88 days after the diagnosis of SR-GvHD (range: 12-802) with 55% of these deaths occurring in the first 100 days. Bacterial infections were the main cause of IRM (20/29), followed by IFI and pneumonia by a community respiratory virus (4/29 cases each). Disease relapse was the primary cause of death in only 5 cases (3.9%).
Risk factors for IRM Predictors of IRM are shown in Table 4 . In multivariate analysis variables with an impact on IRM were: (i) use of rituximab in the 6 months before alloSCT (HR 4.2; 95% CI 1.1-16.3); (ii) severe infection prior to the onset of SR-GvHD (HR 5.8; 95% CI 1.3-26.3); and (iii) a serum C-reactive protein415 IU/mL at the start of salvage treatment (HR 2.9; 95% CI 1.1-8.5).
Late severe infections and IRM in SR-GvHD long-term survivors Twenty-one patients (17%) were alive and disease-free for 41 year after SR-GvHD onset. Nearly all (90%) developed one or more late severe infection. Two patients with moderate cGvHD developed sepsis caused by encapsulated bacteria and five (24%) had community respiratory virus-associated pneumonia. Five cases of severe HSV or VZV infections were documented. Eleven of these 21 patients died at a median of 870 days (range, 369-3723) after the onset of SR-GvHD. Chronic GvHD was considered the primary cause of death in 56% of the patients followed by opportunistic infections (26%) and disease relapse (18%). Abbreviations: 95% CI = 95% confidence interval; Cum.Inc. = cumulative incidence; HR = Hazard ratio; IRM = infection-related mortality; K-M = Kaplan-Meier probability; NA = not applicable. (as analysis of 4-year NRM and its inclusion in the multivariate analysis is not possible owing to the more recent use of etanercept and thus the shorter follow-up in survivors (see Table 1 )). Other variables tested in the univariate analyses included: recipient and donor sex, disease phase, Hematopoietic stem cell transplantation Comorbidity Index, EBMT score, Disease-risk Index score, prior SCT, year of SCT, source of stem cells, conditioning regimen, use of TBI, donor type, CMV serostatus, MoAb as first-salvage treatment, overall grade of SR-GvHD, prophylaxis with broad spectrum antifungal, and monocyte, neutrophil and platelet counts at the onset of salvage therapy. All these variables had a P-value40.5 in univariate analysis and are thus not included in the table. Infections after steroid-refractory acute GvHD I García-Cadenas et al DISCUSSION Although opportunistic infections are a well-known cause of morbi-mortality in recipients of an alloSCT, the rates of the different infections and their impact on NRM after SR-GvHD have been scarcely analyzed. [11] [12] [13] [14] In the current study, most severe infections occurred within 100 days from the onset of SR-GvHD, and the 1-year incidence of bacterial, viral and fungal infections was 74%, 65% and 14%, respectively. The incidence of pathogendefined 4-year IRM was 46%, and bacterial infections were the most common lethal infections. A recent detailed analysis of the infectious complications among 250 alloSCT recipients enrolled in the BMT CTN 0201 trial showed that 79.7% of patients developed at least 1 infection 2 years after SCT. Nevertheless, the 2-year CI of invasive aspergillosis and CMV infection in seropositive recipients were 3.6% and 36.9%, respectively, with infections listed as the primary cause of death in only 5% of patients who died. 15 However, the impact of SR-GvHD was not analyzed in this study.
A significant finding in this study was the high rate (37%) of enterococcal infections, despite the rarity of vancomycin-resistant Enteorococcus faecium cases in our institutions. This is in line with recent studies on the role of the 'pathogenic' intestinal microbiome in patients with active GI GvHD, 16 who suffer a major loss of bacterial diversity with predominant and prolonged persistence of enterococci. There is still no evidence as to whether this overgrowth is involved in the development of GI GvHD or is merely a surrogate marker of disease severity. 17 Nevertheless, these changes, combined with the loss of the protective GI barrier and antibiotic selection explain the high rates of breakthrough enterococcal bloodstream infections.
Unfortunately, the number of events in our study was not high enough to detect the potential poor prognosis associated with enterococcal infections, as reported previously. 18 In terms of viral infection, the rate of BK polyomavirushemorrhagic cystitis was high (15%), as expected, in contrast to the low incidence of EBV reactivation. 19, 20 Perhaps surprisingly, the mortality from IFI, CMV disease and other severe viral infections was low, supporting the efficacy of currently available strategies for the prophylaxis, and early diagnosis-based (or pre-emptive) treatments of these life-threatening infections. 21 Importantly, our data demonstrate that non-Aspergillus mold infections remain uncommon in our centers, even in these very high-risk patients. 22 Variables found to significantly worsen the 4-year-IRM included the use of rituximab in the 6 months before SCT, prior severe infection and a baseline serum C-reactive protein level 415 IU/mL. No other classical risk factors such as disease phase or HCT-CI were associated with IRM, which is probably the consequence of patient heterogeneity and the 15-year study period. In addition, we speculate that, once established, the strongly debilitating effect on the immune system of GvHD and its intensive management minimizes the influence of pre-alloSCT variables, which have a strong predictive impact before SCT. 23, 24 Prior studies have demonstrated a close relationship between the severity of post-SCT complications and the magnitude of C-reactive protein release, which has been considered an independent prognostic factor. [25] [26] [27] Moreover, we found that a severe infection before SR-GvHD was a significant risk factor for IRM. This finding may simply be related to the fact that host factors which increase the risk of an early severe infection are still relevant a few weeks later during treatment of SR-GvHD. Finally, the observation regarding rituximab is intriguing and deserves further investigation. However, owing to the small sample size, we were not able to evaluate the specific contribution of well-known rituximab side effects such as hypogammaglobulinemia or lateonset neutropenia on the risk of severe infections and IRM. 28 An interesting finding was that none of the 11 patients who received sirolimus-based GvHD prophylaxis died from an infection.
In addition, a trend toward a lower IRM was observed in patients rescued with etanercept. However, we would like to emphasize the suggestions made by Martin et al. 29 in a 2012 review, who highlight that no valid conclusions can be made regarding the efficacy of salvage therapies for SR-GvHD from retrospective studies. An apparently paradoxical finding is that despite improvements in supportive care over the past 2 decades, the survival of patients with SR-GvHD has not improved over time and IRM is still a major contributing cause of death in this setting. This finding is in line with recently published studies. 30 Our study, of course, shares the limitations inherent to all retrospective analyses of complex clinical scenarios, including the inability to assign any specific severe infection(s) as the primary or secondary causes of death in patients with active severe SR-GvHD at the time of this infection. In addition, we were not able to evaluate the impact of the cumulative steroid dose on outcomes, which seems particularly important in this setting. 31 With a median follow-up for survivors of 10 years, the estimated rate of 1-year and 4-year OS were poor, 24% and 15%, respectively. The introduction of anti-cytokine therapy failed to improve the dismal prognosis of severe SR-GvHD and was associated with a high rate of opportunistic infections. Especially worrisome is the high rate of bacteremia; although barely present in the current patient series, the proportions of multi-drug resistant Gram-negative and Gram-positive bacteria are rising worldwide, and death due to these infections is expected to increase in the near future. 32 Patients with SR-GvHD are, of course, the perfect hosts for such life-threatening multi-drug resistant bacterial infections. As the ability to prevent, diagnose and treat the broad range of potential opportunistic infections that may occur is limited, only increasing the response of SR-GvHD with a concomitant improvement of innate and pan-specific immune responses may one day lead to long-term GvHD and severe infection-free survival.
